BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 10496343)

  • 21. Release of soluble urokinase receptor from vascular cells.
    Chavakis T; Willuweit AK; Lupu F; Preissner KT; Kanse SM
    Thromb Haemost; 2001 Aug; 86(2):686-93. PubMed ID: 11522023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo.
    Sato S; Kopitz C; Grismayer B; Beaufort N; Reuning U; Schmitt M; Luther T; Kotzsch M; Krüger A; Magdolen V
    Breast Cancer Res Treat; 2011 Jun; 127(3):649-57. PubMed ID: 20635136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adenovirus-mediated antisense urokinase-type plasminogen activator receptor gene transfer reduces tumor cell invasion and metastasis in non-small cell lung cancer cell lines.
    Lakka SS; Rajagopal R; Rajan MK; Mohan PM; Adachi Y; Dinh DH; Olivero WC; Gujrati M; Ali-Osman F; Roth JA; Yung WK; Kyritsis AP; Rao JS
    Clin Cancer Res; 2001 Apr; 7(4):1087-93. PubMed ID: 11309361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of urokinase-type plasminogen activator receptor is correlated with metastases of lingual squamous cell carcinoma.
    Wang J; Guo F; Wei H; Dong J; Wu J
    Br J Oral Maxillofac Surg; 2006 Dec; 44(6):515-9. PubMed ID: 16356605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients].
    Zhou Q; Liang LJ; Peng BG; Zhen YY
    Ai Zheng; 2006 Nov; 25(11):1433-8. PubMed ID: 17094916
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor.
    Henic E; Sixt M; Hansson S; Høyer-Hansen G; Casslén B
    Gynecol Oncol; 2006 Apr; 101(1):28-39. PubMed ID: 16263158
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heregulin regulation of urokinase plasminogen activator and its receptor: human breast epithelial cell invasion.
    Mazumdar A; Adam L; Boyd D; Kumar R
    Cancer Res; 2001 Jan; 61(1):400-5. PubMed ID: 11196194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
    Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
    BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin-6 infusion during human endotoxaemia inhibits in vitro release of the urokinase receptor from peripheral blood mononuclear cells.
    Ostrowski SR; Plomgaard P; Fischer CP; Steensberg AS; Møller K; Høyer-Hansen G; Pedersen BK; Ullum H
    Scand J Immunol; 2005 Feb; 61(2):197-206. PubMed ID: 15683457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer.
    Riisbro R; Christensen IJ; Piironen T; Greenall M; Larsen B; Stephens RW; Han C; Høyer-Hansen G; Smith K; Brünner N; Harris AL
    Clin Cancer Res; 2002 May; 8(5):1132-41. PubMed ID: 12006529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours.
    de Witte JH; Foekens JA; Brünner N; Heuvel JJ; van Tienoven T; Look MP; Klijn JG; Geurts-Moespot A; Grebenchtchikov N; Benraad T; Sweep CG
    Br J Cancer; 2001 Jul; 85(1):85-92. PubMed ID: 11437407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
    J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Urokinase receptor variants in tissue and body fluids.
    Høyer-Hansen G; Lund IK
    Adv Clin Chem; 2007; 44():65-102. PubMed ID: 17682340
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.
    Ecke TH; Schlechte HH; Schulze G; Lenk SV; Loening SA
    Anticancer Res; 2005; 25(1B):635-41. PubMed ID: 15816639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of hormones on uPA, PAI-1 and suPAR from cultured endometrial and ovarian endometriotic stromal cells.
    Guan YM; Carlberg M; Bruse C; Carlström K; Bergqvist A
    Acta Obstet Gynecol Scand; 2002 May; 81(5):389-97. PubMed ID: 12027810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
    Stillfried GE; Saunders DN; Ranson M
    Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer.
    Carriero MV; Del Vecchio S; Capozzoli M; Franco P; Fontana L; Zannetti A; Botti G; D'Aiuto G; Salvatore M; Stoppelli MP
    Cancer Res; 1999 Oct; 59(20):5307-14. PubMed ID: 10537314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasminogen activator system in oral squamous cell carcinoma.
    Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
    Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma.
    Zannetti A; Del Vecchio S; Carriero MV; Fonti R; Franco P; Botti G; D'Aiuto G; Stoppelli MP; Salvatore M
    Cancer Res; 2000 Mar; 60(6):1546-51. PubMed ID: 10749121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity.
    Pawlak K; Pawlak D; Mysliwiec M
    Thromb Res; 2007; 119(4):475-80. PubMed ID: 16828495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.